Pharmacokinetic and Pharmacodynamic Equivalence of Epoetin Hospira and Epogen After Single Subcutaneous Doses to Healthy Male Subjects.

Stalker, Dennis; Reid, Susan; Ramaiya, Atulkumar; Wisemandle, Wayne A; Martin, Nancy E

Stalker, Dennis; Reid, Susan; Ramaiya, Atulkumar; Wisemandle, Wayne A; Martin, Nancy E.

Affiliation

Stalker D; Global Clinical Development, Hospira, Inc, Lake Forest, Illinois. Electronic address: dennis.stalker@hospira.com.
Reid S; Global Clinical Development, Hospira, Inc, Lake Forest, Illinois.
Ramaiya A; Global Clinical Development, Hospira, Inc, Lake Forest, Illinois.
Wisemandle WA; Global Clinical Development, Hospira, Inc, Lake Forest, Illinois.
Martin NE; Global Clinical Development, Hospira, Inc, Lake Forest, Illinois.

Clin Ther ; 38(8): 1778-88, 2016 Aug.

Article in En | MEDLINE | ID: mdl-27473384

Subject(s)

Epoetin Alfa/administration & dosage; Recombinant Proteins/administration & dosage; Adolescent; Adult; Antibodies, Neutralizing/immunology; Cross-Over Studies; Epoetin Alfa/pharmacokinetics; Epoetin Alfa/pharmacology; Humans; Male; Middle Aged; Recombinant Proteins/pharmacokinetics; Recombinant Proteins/pharmacology; Young Adult

Key words

biosimilar; epoetin alfa; equivalence; erythropoietin; pharmacodynamics; pharmacokinetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Proteins / Epoetin Alfa Type of study: Clinical_trials Limits: Adolescent / Adult / Humans / Male / Middle aged Language: En Journal: Clin Ther Year: 2016 Type: Article

Fulltext

XML

PubMed Links

Search on Google